Category: Pharmacogenomics

Approximately 15–20% of the Asian population are CYP2C19 poor metabolizers, a genetic variation that significantly alters how the body processes omeprazole. This critical enzyme pathway dictates an individual's response to the drug and can lead to vastly different therapeutic outcomes.

Approximately 1 in 300 people have a complete deficiency of the thiopurine S-methyltransferase (TPMT) enzyme, putting them at high risk for severe drug toxicity. This article explains what is TPM in medicine by focusing on the crucial role of TPMT in personalizing treatment.

Approximately 3 to 5% of the population has a reduced function of the DPD enzyme, a condition known as DPD deficiency, which significantly increases the risk of severe toxicity from certain chemotherapy drugs. This fact highlights why it is critical to understand that the query 'What is the drug DPD?' is based on a fundamental misconception, as DPD refers to an enzyme, not a medication.